Interstitial Lung Disease: A Review
TM Maher - JAMA, 2024 - jamanetwork.com
Importance Interstitial lung disease (ILD) consists of a group of pulmonary disorders
characterized by inflammation and/or fibrosis of the lung parenchyma associated with …
characterized by inflammation and/or fibrosis of the lung parenchyma associated with …
Nutrition in patients with idiopathic pulmonary fibrosis: critical issues analysis and future research directions
P Faverio, M Bocchino, A Caminati, A Fumagalli… - Nutrients, 2020 - mdpi.com
In idiopathic pulmonary fibrosis (IPF), several factors may have a negative impact on the
nutritional status, including an increased respiratory muscles load, release of inflammation …
nutritional status, including an increased respiratory muscles load, release of inflammation …
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease
YH Khor, V Cottin, AE Holland, Y Inoue… - European …, 2023 - Eur Respiratory Soc
Interstitial lung disease (ILD) is a diverse group of inflammatory and fibrotic lung conditions
causing significant morbidity and mortality. A multitude of factors beyond the lungs influence …
causing significant morbidity and mortality. A multitude of factors beyond the lungs influence …
Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease
A Comes, AW Wong, JH Fisher, J Morisset… - Chest, 2022 - Elsevier
Background Mortality risk assessment in interstitial lung disease (ILD) is challenging. Our
objective was to determine the prognostic significance of BMI and change in weight in the …
objective was to determine the prognostic significance of BMI and change in weight in the …
[HTML][HTML] Endocrine and metabolic factors and the risk of idiopathic pulmonary fibrosis: a mendelian randomization study
Y Jiang, R Chen, S Xu, Y Ding, M Zhang… - Frontiers in …, 2024 - frontiersin.org
Background: Previous observational studies have investigated the association between
endocrine and metabolic factors and idiopathic pulmonary fibrosis (IPF), yet have produced …
endocrine and metabolic factors and idiopathic pulmonary fibrosis (IPF), yet have produced …
Geriatric Nutritional Risk Index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis
Y Mochizuka, Y Suzuki, M Kono, H Hasegawa… - …, 2023 - Wiley Online Library
Abstract Background and Objective Idiopathic pulmonary fibrosis (IPF) is characterized by
progressive lung fibrosis of unknown aetiology. Epidemiological studies have suggested …
progressive lung fibrosis of unknown aetiology. Epidemiological studies have suggested …
Ectopic and visceral fat deposition in aging, obesity, and idiopathic pulmonary fibrosis: an interconnected role
X Cheng, S Jiang, B Pan, W Xie, J Meng - Lipids in Health and Disease, 2023 - Springer
Idiopathic pulmonary fibrosis (IPF) is considered an age-related disease. Age-related
changes, along with other factors such as obesity, hormonal imbalances, and various …
changes, along with other factors such as obesity, hormonal imbalances, and various …
Post hoc analysis of clinical outcomes in placebo-and pirfenidone-treated patients with IPF stratified by BMI and weight loss
S Jouneau, B Crestani, R Thibault, M Lederlin… - Respiration, 2022 - karger.com
Background: Weight loss is frequently reported in patients with idiopathic pulmonary fibrosis
(IPF) and may be associated with worse outcomes in these patients. Objective: The aim of …
(IPF) and may be associated with worse outcomes in these patients. Objective: The aim of …
A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease
Background Comorbidities are frequent and have been associated with poor quality of life,
increased hospitalizations, and mortality in patients with interstitial lung disease (ILD) …
increased hospitalizations, and mortality in patients with interstitial lung disease (ILD) …
[HTML][HTML] Idiopathic pulmonary fibrosis: a review of disease, pharmacological, and nonpharmacological strategies with a focus on symptoms, function, and health …
D Rozenberg, N Sitzer, S Porter, A Weiss… - Journal of Pain and …, 2020 - Elsevier
Despite several advances in treatment, idiopathic pulmonary fibrosis (IPF) remains a
progressive, symptomatic, and terminal disease in patients not suitable for lung …
progressive, symptomatic, and terminal disease in patients not suitable for lung …